Welcome to the November 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we highlight two important research articles in the disease state, including study results showing an increased risk of MPN development among smokers and the exciting potential of using prognostic models to personalize clinical outcome predictions in patients with MPNs.
We also spotlight two recent articles on myelofibrosis (MF) reporting the results from a study of ruxolitinib/azacitidine combination therapy and providing an interactive case study of the diagnosis and management of a patient with MF. Additionally this month, we explore the impact of thrombotic events on healthcare costs among patients with polycythemia vera (PV) receiving hydroxyurea and how the use of phlebotomy and hydroxyurea in older patients with PV affects overall survival and thrombosis risk.
Don’t forget about our other handy MPN management resources:
As always, I hope you find this newsletter and its contents to be a useful and enduring resource in your practice. Please feel free to share it with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at email@example.com at any time.
Lindsey Lyle, MS, PA-C
Senior Instructor, Blood Cancers and Bone Marrow Transplant Program
University of Colorado, Anschutz Medical Campus